Charting
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
well the o/s been growing daily and since its been under .07 so not sure how that is
Its not shorts its dilution ! They dilute north of 10 mill shares per day !everyday
You think word got out yet about the news? heheee
Hey Tesla havnt they been diluting around 10 mill per day on average? I been seeing your TA checks daily seems to me they dump like 10 mill per day. By my calculations they had roughly 60 mill left as of yesterday so we may see the end after this week of the diltution until they raise a/s and or do the r/s
See perfect example they try to sucker in buyers then crash the bids. Stop donating to them guy let make them dump this thing to .01
It may bounce once they max the o/s then it will prob get a bounce before they can r/s but that could be in the .01-.03 range by then . As they have 60 mill more shares left by my count 203 mill o/s 42 mill held by insiders . Leaves 60 mill more to dump . The debt holders could careless what price to sell at they get thier $ no matter what the pps
No they take arca back to let traders think it could be bounce time let it ut a few ticks then bring him back and hit the bids . Been doing this since .10+
well when your company stock falls from 19 bucks to .04 cents you may need to address your shareholder base...
What amazes me is the email the ceo sent saying no r/s and also that he would have a shareholder letter out soon as they figured out what was goign on..lol I mean he clearly knew what was going on he took the death spiral fincance
They have 60 mill to convert and sell thats why. Wont stop until they run out and then they will wait for the r/s and a/s and continue where they left off. This will be in play again at these levels in summer. Death spiral
at this point everyone should just stop bidding and make them dump this thing much lower. They are clearly goign to continue to sit on the ask and downtrend this into the black whole. -20%+ each day lower and lower never seen relentless selling like this even on pos penny plays . This one was suppose to be ran by Titans!
You cant even flip this thing now constant sell pressure from the debt converters. 300 mill a/s last o/s count was 203 mill. Insiders own 42 mill so roughly 60 mill to convert until the a/s and or r/s raise .. Unreal worst dream team I have ever seen
So 202 mill o/s and insiders own what 42 mill roughly ? So now the question is will 60 more mill be sold into the market before the dilution stops . This will bounce but from where is a guess .05 support or if that fails then lower but the potential r/s is around 2 months away. When the dumping stops the bounce will happen no question . Never seen such relentless selling though that's for sure
There just went the HOD
Yep many months away from a a/s or r/s . Lots can change between now and then. They are clearly concerned with a hostile takeover. Not over here by a long shot but expect it to be volatile no doubt. I suspect big boyz that have been buying will continue to gobble up as many as they can as others sell.
R/S is off the table
https://twitter.com/throwdownbev/with_replies
The pending r/s filing was 1 for 10 not 1:100 .
Company saying on twitter they are trying to avoid the r/s all together now
Updates can be seen here
https://twitter.com/throwdownbev/with_replies
Nice find
I see more and more small Bio companies are getting funded from gov to fast track potential vaccines . GOVX with any funding or backing could explode this small Bio company like IBIO has. Be interesting to see what the future brings for GOVX.
OTC having issues all around
OTC Markets Group ?@OTCMarkets 3m3 minutes ago
OTC Link ATS is experiencing system issues. OTC Link markets closed, quoting & messaging will resume in approx 5-7 min. Updates to follow.
OTC having issues all around
OTC Markets Group ?@OTCMarkets 3m3 minutes ago
OTC Link ATS is experiencing system issues. OTC Link markets closed, quoting & messaging will resume in approx 5-7 min. Updates to follow.
OTC having issues all around
OTC Markets Group ?@OTCMarkets 3m3 minutes ago
OTC Link ATS is experiencing system issues. OTC Link markets closed, quoting & messaging will resume in approx 5-7 min. Updates to follow.
I never even noticed that until you brought the subject up. Nice dd
GeoVax is a clinical-stage biotechnology company developing innovative human vaccines using our novel DNA/MVA platform technology.
Our proprietary vaccine technology has been developed through multi-year collaborations with the US National Institutes of Health, the US Centers for Disease Control and Prevention, and Emory University. Our mission is to apply our expertise in areas where there is a significant unmet medical need and commercial opportunity with the goal of improving the lives of people affected by serious and life-threatening diseases.
Our primary focus is to develop vaccines that prevent and fight Human Immunodeficiency Virus (HIV) infections and we have recently expanded our research and development efforts to include vaccines to prevent Ebola virus infection.
We know our work could affect the lives of millions worldwide, and we invite you to join our effort.
IBIO would of been nice to be in on that news and big gap up. wow
Love to see GOVX get news like that
I would love to see the beverage hit retail shelves. With the chairman that is on board here I would think he has big connection to make that happen.
http://finance.yahoo.com/news/peter-w-busch-appointed-chairman-124500255.html
Twitter feed is here https://twitter.com/throwdownbev
Twitter update says news next week. Could be on the fact that all the debt is converted . last week they said 85% was done and that they would send out press telling shareholders once the debt was finished. They also said they are working on something big. Should get intersting here in the coming days weeks..
Ebola Is Airborne, University Of Minnesota CIDRAP Researchers Claim
ebola
Ebola is airborne, according to a new report by the Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota. Researchers at the university just advised the World Health Organization (WHO) and the Centers for Disease Control (CDC) that “scientific and epidemiologic evidence” now exists that proves Ebola has the potential to be transmitted via exhaled breath and “infectious aerosol particles.”
University of Minnesota CIDRAP scientists are now warning both health care providers and the general public that surgical facemasks will not prevent the transmission of Ebola. According to the airborne Ebola report, medical workers must immediately be given full-hooded protective gear and powered air-purifying respirators. CIDRAP has reportedly been a worldwide leader in addressing public health and safety concerns and preparedness since 2001.
An excerpt from the CIDRAP report reads, “Healthcare workers play a very important role in the successful containment of outbreaks of infectious diseases like Ebola. The correct type and level of personal protective equipment (PPE) ensures that healthcare workers remain healthy throughout an outbreak—and with the current rapidly expanding Ebola outbreak in West Africa, it’s imperative to favor more conservative measures.”
The University of Minnesota report goes on to note that any action which can be taken to “reduce risk” of Ebola exposure should not wait until a “scientific certainty” develops. “The minimum level of protection in high-risk settings should be a respirator with an assigned protection factor greater than 10. A powered air-purifying respirator (PAPR) with a hood or helmet offers many advantages over an N95 filtering facepiece or similar respirator, being more protective, comfortable, and cost-effective in the long run,” the CIDRAP report also adds.
The working theory about Ebola transmission currently being uttered by the CDC and the agency’s director Thomas Frieden, is incorrect and “outmoded” according to the University of Minnesota CIDRAP report. “Virus-laden bodily fluids may be aerosolized and inhaled while a person is in proximity to an infectious person and that a wide range of particle sizes can be inhaled and deposited throughout the respiratory tract,” University researchers concluded. Background information detailing why CIDRAP believes the CDC and WHO are function under an outdated mode of thought when it comes to how infectious diseases are transmitted via aerosols is also included in the new report.
ADVERTISEMENT
“Medical and infection control professionals have relied for years on a paradigm for aerosol transmission of infectious diseases based on very outmoded research and an overly simplistic interpretation of the data. In the 1940s and 50s, William F. Wells and other ‘aerobiologists’ employed now significantly out-of-date sampling methods (eg, settling plates) and very blunt analytic approaches (eg, cell culturing) to understand the movement of bacterial aerosols in healthcare and other settings. Their work, though groundbreaking at the time, provides a very incomplete picture,” the report said.
According to CIDRAP researchers, early aerobiologists were unable to measure small particles near an infected person and therefore made an assumption that such particles existed on far from the source and airborne transmission could of happened around 3-feet or so from the source.
Do you think about airborne Ebola? Should flight restrictions and mandatory quarantines be enacted in order to prevent an Ebola pandemic in America?
Read more at http://www.inquisitr.com/1541821/ebola-is-airborne-university-of-minnesota-cidrap-researchers-claim/#jtzQVEozoAEzgb5p.99
Ebola Is Airborne, University Of Minnesota CIDRAP Researchers Claim
ebola
Ebola is airborne, according to a new report by the Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota. Researchers at the university just advised the World Health Organization (WHO) and the Centers for Disease Control (CDC) that “scientific and epidemiologic evidence” now exists that proves Ebola has the potential to be transmitted via exhaled breath and “infectious aerosol particles.”
University of Minnesota CIDRAP scientists are now warning both health care providers and the general public that surgical facemasks will not prevent the transmission of Ebola. According to the airborne Ebola report, medical workers must immediately be given full-hooded protective gear and powered air-purifying respirators. CIDRAP has reportedly been a worldwide leader in addressing public health and safety concerns and preparedness since 2001.
An excerpt from the CIDRAP report reads, “Healthcare workers play a very important role in the successful containment of outbreaks of infectious diseases like Ebola. The correct type and level of personal protective equipment (PPE) ensures that healthcare workers remain healthy throughout an outbreak—and with the current rapidly expanding Ebola outbreak in West Africa, it’s imperative to favor more conservative measures.”
The University of Minnesota report goes on to note that any action which can be taken to “reduce risk” of Ebola exposure should not wait until a “scientific certainty” develops. “The minimum level of protection in high-risk settings should be a respirator with an assigned protection factor greater than 10. A powered air-purifying respirator (PAPR) with a hood or helmet offers many advantages over an N95 filtering facepiece or similar respirator, being more protective, comfortable, and cost-effective in the long run,” the CIDRAP report also adds.
The working theory about Ebola transmission currently being uttered by the CDC and the agency’s director Thomas Frieden, is incorrect and “outmoded” according to the University of Minnesota CIDRAP report. “Virus-laden bodily fluids may be aerosolized and inhaled while a person is in proximity to an infectious person and that a wide range of particle sizes can be inhaled and deposited throughout the respiratory tract,” University researchers concluded. Background information detailing why CIDRAP believes the CDC and WHO are function under an outdated mode of thought when it comes to how infectious diseases are transmitted via aerosols is also included in the new report.
ADVERTISEMENT
“Medical and infection control professionals have relied for years on a paradigm for aerosol transmission of infectious diseases based on very outmoded research and an overly simplistic interpretation of the data. In the 1940s and 50s, William F. Wells and other ‘aerobiologists’ employed now significantly out-of-date sampling methods (eg, settling plates) and very blunt analytic approaches (eg, cell culturing) to understand the movement of bacterial aerosols in healthcare and other settings. Their work, though groundbreaking at the time, provides a very incomplete picture,” the report said.
According to CIDRAP researchers, early aerobiologists were unable to measure small particles near an infected person and therefore made an assumption that such particles existed on far from the source and airborne transmission could of happened around 3-feet or so from the source.
Do you think about airborne Ebola? Should flight restrictions and mandatory quarantines be enacted in order to prevent an Ebola pandemic in America?
Read more at http://www.inquisitr.com/1541821/ebola-is-airborne-university-of-minnesota-cidrap-researchers-claim/#jtzQVEozoAEzgb5p.99
Ebola vaccine
GOVX working on Ebola vaccine
Zacks raise price target to $1.50
http://scr.zacks.com/News/Press-Releases/Press-Release-Details/2014/GOVX-GeoVax-Expands-Pipeline-by-Initiating-Ebola-Vaccine-Development-Program/default.aspx
Ebola vaccine
GOVX working on Ebola vaccine
Zacks raise price target to $1.50
http://scr.zacks.com/News/Press-Releases/Press-Release-Details/2014/GOVX-GeoVax-Expands-Pipeline-by-Initiating-Ebola-Vaccine-Development-Program/default.aspx
David Dodd, Chairman of GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines using its novel DNA/MVA platform technology, was recently interviewed on the Fox Business Network’s The Willis Report and by Dana Loesch on Glenn Beck’s digital outlet, TheBlaze TV, discussing GeoVax’s initiation of an Ebola development program and perspective on the fast-moving global epidemic.
To view the Fox Business Network interview in its entirety, please visit the following link: http://www.foxbusiness.com/on-air/willis-report/videos#p/157870/v/3818202793001
To view the interview on TheBlaze TV, please visit the following link: http://www.video.theblaze.com/media/video.jsp?content_id=36764233
GeoVax announced on October 2, 2014 that it is developing two Ebola vaccines, GOVX-E301 and GOVX-E302. Both are recombinant MVA (modified vaccinia Ankara) vaccines designed to produce non-infectious virus-like particles (VLPs) displaying the Ebola virus glycoprotein. GOVX-E301 is being developed as a single-dose vaccine for epidemic response against the ZEBOV strain of Ebola, the virus responsible for the current outbreak. GOVX-E302 is being developed for routine immunization and is designed to protect against all three versions of Ebola known to be lethal in humans.
To facilitate its Ebola vaccine development efforts, GeoVax plans to collaborate with experts at the U.S. Centers for Disease Control (CDC) in Atlanta with access to Biosafety Level 4 (BSL-4) facilities for testing vaccine responses. The Company has set a goal of having its GOVX-E301 vaccine produced and ready for use in humans within eighteen months.
About GeoVax
GeoVax Labs, Inc. (OTCQB: GOVX) is a biotechnology company developing human vaccines using its novel DNA/MVA vaccine delivery platform. The Company’s lead development program is focused on vaccines to prevent, and treat, Human Immunodeficiency Virus (HIV) infections. GeoVax’s unique, two component vaccine, a recombinant DNA and a recombinant modified vaccinia Ankara (MVA), is designed to stimulate both anti-HIV antibody and anti-HIV T cell immune responses. GeoVax’s DNA and MVA vaccines are used in a prime/boost protocol in which priming is done with the DNA and boosting with the MVA. Both the DNA and MVA express the three major proteins of the HIV virus: Gag, Pol, and Env, and produce non-infectious virus-like-particles. GeoVax’s vaccines are unique in expressing virus-like particles that display the native form of the trimeric membrane-bound HIV-1 envelope glycoprotein. Clinical trials for GeoVax’s preventive HIV vaccines have been conducted by the US National Institutes of Health-supported HIV Vaccine Trials Network (HVTN) with funding from the National Institute of Allergy and Infectious Disease (NIAID). Overall, GeoVax’s vaccines, in various doses and combinations, have been tested in close to 500 humans. www.geovax.com.
Forward-Looking Statements
Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent HIV or Ebola infection in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission including those set forth at "Risk Factors" in GeoVax's Form 10-K.
INVESTOR CONTACT
Adam S. Holdsworth
ProActive Capital Group
646.862.4607
David Dodd, Chairman of GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines using its novel DNA/MVA platform technology, was recently interviewed on the Fox Business Network’s The Willis Report and by Dana Loesch on Glenn Beck’s digital outlet, TheBlaze TV, discussing GeoVax’s initiation of an Ebola development program and perspective on the fast-moving global epidemic.
To view the Fox Business Network interview in its entirety, please visit the following link: http://www.foxbusiness.com/on-air/willis-report/videos#p/157870/v/3818202793001
To view the interview on TheBlaze TV, please visit the following link: http://www.video.theblaze.com/media/video.jsp?content_id=36764233
GeoVax announced on October 2, 2014 that it is developing two Ebola vaccines, GOVX-E301 and GOVX-E302. Both are recombinant MVA (modified vaccinia Ankara) vaccines designed to produce non-infectious virus-like particles (VLPs) displaying the Ebola virus glycoprotein. GOVX-E301 is being developed as a single-dose vaccine for epidemic response against the ZEBOV strain of Ebola, the virus responsible for the current outbreak. GOVX-E302 is being developed for routine immunization and is designed to protect against all three versions of Ebola known to be lethal in humans.
To facilitate its Ebola vaccine development efforts, GeoVax plans to collaborate with experts at the U.S. Centers for Disease Control (CDC) in Atlanta with access to Biosafety Level 4 (BSL-4) facilities for testing vaccine responses. The Company has set a goal of having its GOVX-E301 vaccine produced and ready for use in humans within eighteen months.
About GeoVax
GeoVax Labs, Inc. (OTCQB: GOVX) is a biotechnology company developing human vaccines using its novel DNA/MVA vaccine delivery platform. The Company’s lead development program is focused on vaccines to prevent, and treat, Human Immunodeficiency Virus (HIV) infections. GeoVax’s unique, two component vaccine, a recombinant DNA and a recombinant modified vaccinia Ankara (MVA), is designed to stimulate both anti-HIV antibody and anti-HIV T cell immune responses. GeoVax’s DNA and MVA vaccines are used in a prime/boost protocol in which priming is done with the DNA and boosting with the MVA. Both the DNA and MVA express the three major proteins of the HIV virus: Gag, Pol, and Env, and produce non-infectious virus-like-particles. GeoVax’s vaccines are unique in expressing virus-like particles that display the native form of the trimeric membrane-bound HIV-1 envelope glycoprotein. Clinical trials for GeoVax’s preventive HIV vaccines have been conducted by the US National Institutes of Health-supported HIV Vaccine Trials Network (HVTN) with funding from the National Institute of Allergy and Infectious Disease (NIAID). Overall, GeoVax’s vaccines, in various doses and combinations, have been tested in close to 500 humans. www.geovax.com.
Forward-Looking Statements
Certain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent HIV or Ebola infection in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so. More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission including those set forth at "Risk Factors" in GeoVax's Form 10-K.
INVESTOR CONTACT
Adam S. Holdsworth
ProActive Capital Group
646.862.4607
GOVX to make a Ebola vaccine